Bone Metabolism After Bariatric Surgery
Completed
Conditions studied: Obesity, Osteoporosis
In brief
The purpose and objective of this study is to determine the changes in bone metabolism after bariatric surgery in postmenopausal women. This is a prospective cohort study that will enroll up to 40 postmenopausal female subjects with class II and III obesity from the Duke Center for Metabolic and Weight Loss Surgery. The study team will enroll subjects that are already being scheduled for either sleeve gastrectomy or Roux-en-Y gastric bypass. The osteoclast activity, the osteoblast activity, and the bone mineral density will be measured in all subjects preoperatively and 12 months postoperatively through research specific blood tests and Dual energy x-ray Absorptiometry (DEXA) scans. The primary endpoints are change in osteoclast activity as measured by C-terminal telopeptide of type I collagen and change in bone density as measured by DEXA scan. These are continuous variable and given the small sample size the investigators will use a nonparametric Wilcoxon rank-sum test to compare the difference in one year change in these variables. There is a slight risk of loss of confidentiality. Every effort will be made to protect all PHI. There is also the risk of increased exposure to radiation from the DEXA scans performed twice with each subjects participating in the study.
Key facts
- Study ID
- NCT01824797
- Run by
- Duke University
- People needed
- 42
- Starts
- 2013-05-01
- Expected to finish
- 2018-05-31
- Last updated by the study team
- 2019-08-16
Who can join
Age: 40 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Postmenopausal women as determined by having a history of no menstrual bleed for greater than one year.
- Body Mass Index ≥35 kg/m² and stable weight for the previous 3 months.
- Able to speak and read English.
- Being scheduled for either Roux-en-Y gastric bypass or sleeve gastrectomy.
You may not qualify if…
- A documented history of osteoporosis or currently receiving medical treatment for osteoporosis with bisphosphonates, teriparatide, raloxifene, or denosumab.
- Weight greater than 295 pounds as this is the weight limit for our Dual-energy X-ray absorptiometry machine.
- Current or past (less than 1 year from enrollment) usage of estrogen hormone replacement therapy.
- Current smoker
- Any history of glucocorticoid use greater than one year in duration or current use of glucocorticoids.
Where it is running
- Duke Center for Metabolic and Weight Loss Surgery — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.